Recently, expression of a tumour-specific constitutively active spliced variant of the receptor (EGFRvIII) was detected in 44% of a small cohort of HNSCCs and found to contribute to enhanced growth and resistance to wild-type EGFR-targeting antibodies (Sok et al, 2006). This evidence concerns the gene EGFR and neoplasm.